VCYT Veracyte, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
22:27
Sep 14
r/biotech_stocks
VCYT bullish on Convergent/UroAmp growth driver
The author argues Veracyte's $150M cash purchase of Convergent Genomics (plus up to $30M in milestones) is a good move, with the UroAmp urine-based tumor DNA bladder cancer test as the key asset. The mechanism is that if Veracyte can scale UroAmp and secure wider adoption and reimbursement, it becomes a meaningful new growth driver for the company. The author states they are more bullish on VCYT after the deal, with no explicit time horizon given. The main stated risk is whether they overpaid for the acquisition.
VCYT Veracyte, Inc. Long 1ST — —

About VCYT Investor Commentary

Across the available history and selected sources, Buzzberg tracks VCYT (Veracyte, Inc.) across 3 sources: 1 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: u/a_moron_in_a_hurry.